Skip to Content

Legal compliance reminder: purchasers must obtain all necessary licenses and comply with applicable laws (see General Terms & Conditions of Sale). We reserve the right to request additional information.

Merck

Skip To

SML2825

I-BET469

≥98% (HPLC)

Promotion Available

Synonym(s):

5-(1-(1,3-Dimethoxypropan-2-yl)-5-morpholino-1H-benzo[d]imidazol-2-yl)-1,3-dimethylpyridin-2(1H)-one, 5-[1-[2-Methoxy-1-(methoxymethyl)ethyl]-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-1,3-dimethyl-2(1H)-pyridinone

Sign In to View Organizational & Contract Pricing.

Spend 10 750 CZK — Save 5%; Spend 15 250 CZK — Save 10%; Spend 28 000 CZK — Save 15%*

Sign in to check eligibility. Shop Products

Select a Size

Change View
Size/SKUAvailabilityPrice
5 mg
Please contact Customer Service for Availability
3 080,00 CZK
25 mg
Please contact Customer Service for Availability
9 620,00 CZK

About This Item

Empirical Formula (Hill Notation):
C23H30N4O4
CAS Number:
Molecular Weight:
426.51
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder

3 080,00 CZK

Save Up To 15%


Please contact Customer Service for Availability

​
Request a Custom Order
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Quality Segment

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

N4(CCOCC4)c1cc2nc([n](c2cc1)C(COC)COC)C3=CN(C(=O)C(=C3)C)C

InChI

1S/C23H30N4O4/c1-16-11-17(13-25(2)23(16)28)22-24-20-12-18(26-7-9-31-10-8-26)5-6-21(20)27(22)19(14-29-3)15-30-4/h5-6,11-13,19H,7-10,14-15H2,1-4H3

InChI key

DDSHVVXWYKDTTQ-UHFFFAOYSA-N

Biochem/physiol Actions

I-BET469 is an orally active bromodomain (BrD) inhibitor with selectivity toward a subset of bromodomain-containng proteins (BCPs) and BrDs (Kd in nM: BRD4 BrD1/2 = 1.5/2.9, BRD3 BrD1/2 = 2/2.3, BRD2 BrD1/2 = 2.3/2.8, BRDT BrD1/2 = 12/100, CREBBP = 37, EP300 = 49; Kd ≥4.8 μM toward 22 other BCPs). I-BET469 targets cellular BRD4 with high affinity (pKd = 8.3 or Kd = 5.0 nM by NanoBRET) and shows in vivo efficacy in a murine acute endotoxic shock model (1, 3, 10 mg/kg po. 30 min prior to LPS) and a chronic T cell-dependent immunization model (IgG suppression on day 14 = 24% and 65%, respectively, with 0.3 mg/kg or 3 mg/kg daily po.).
Orally active bromodomain (BrD) inhibitor with in vivo efficacy and selectivity for BRD2/3/4, BRDT, CREBBP, EP300 over 22 other BCPs.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
SML1184SML2826SML1693
description

≥98% (HPLC)

description

≥98% (HPLC)

description

≥98% (HPLC)

description

≥98% (HPLC)

form

powder

form

powder

form

powder

form

powder

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

100

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: 5 mg/mL, clear (warmed)

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: 1 mg/mL, clear (warmed)

color

white to beige

color

white to beige

color

white to beige

color

white to beige


Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Questions

Reviews

No rating value

Active Filters